11/10/15 - 06:58 AM EST
I'm often criticized for having nothing positive to say about MannKind, so let the record reflect that I believe the company going to Israel to raise money is smart.
11/09/15 - 08:53 AM EST
'The chance you would have gotten similar data giving the patients 10 cups of coffee a day instead? Almost 100%,' said Dr. Adam Kline, a researcher who reviewed the data.
11/08/15 - 12:32 PM EST
Ovarian cancer patients with tumors expressing high levels of a specific protein on their surface respond best to treatment with ImmunoGen's "smart bomb" cancer drug.
11/08/15 - 08:01 AM EST
New results from a study of Agios' AG-120 in patients with solid tumors were presented at a medical meeting Sunday.
11/05/15 - 11:21 AM EST
Can Cellectis transform CAR-T from a cool cancer science experiment into a profitable business?
11/05/15 - 08:01 AM EST
Bluebird Bio is learning differences in the genetic mutation behind beta-thalassemia, a serious, inherited blood disease, is playing a role in how well patients respond to its experimental gene therapy.
11/02/15 - 11:40 AM EST
Biomarin hasn't started confirmatory trials of DMD drug drisapersen suggested by FDA regulators.
11/02/15 - 06:56 AM EST
Th purchase of Dyax strengthens Shire's portfolio of drugs treating a rare swelling disorder.
10/29/15 - 11:26 AM EDT
MannKind's signature product contributed only €2 million to Sanofi's diabetes sales in the third quarter.
10/29/15 - 08:33 AM EDT
Lowering its corporate tax burden is a key motivating factor for New York-based Pfizer in any blockbuster deal with Allergan.